Secures Significant Funding for Late-Stage Clinical Trials

Crystalys Therapeutics, a clinical-stage biotechnology company, has successfully completed a $130 million Series B financing round to accelerate the global Phase 3 clinical trials of dotinurad, its novel candidate for the treatment of gout. The funding round was led by Frazier Life Sciences, a prominent healthcare-focused venture capital firm, with participation from over 20 leading global institutional investors, including Wellington Management and Novo Holdings. The proceeds will be primarily used to fund patient recruitment and operational costs for the ongoing multinational, registration-directed Phase 3 trials, RUBY and TOPAZ. This strategic move aims to address the financial uncertainties associated with late-stage clinical development and expedite the drug's progress.

Targeting Western Markets Based on Asian Approval Data

dotinurad is an innovative, once-daily oral selective URAT1 inhibitor that reduces serum uric acid levels by inhibiting the reabsorption of uric acid in the kidneys. The drug was initially developed by Fuji Yakuhin and has already been approved in several Asian countries, including Japan, China, Taiwan, Thailand, and the Philippines, demonstrating its efficacy and safety. In July 2024, Crystalys Therapeutics acquired global exclusive development and commercialization rights for dotinurad outside of Asia from Urica Therapeutics. With substantial real-world data already available from the Asian market, the company is well-positioned to navigate the regulatory approval process with the FDA and EMA, increasing the likelihood of success in global clinical trials.

Addressing Unmet Needs Beyond Existing Standard Treatments

The global market for gout and hyperuricemia is estimated at approximately $3 billion annually and is growing due to changes in diet and an aging population. However, existing standard treatments, such as allopurinol and febuxostat, which are xanthine oxidase inhibitors, have limitations, including concerns about cardiovascular side effects and insufficient uric acid-lowering effects. Lesinurad, another URAT1 inhibitor, was withdrawn from the market due to significant renal toxicity, highlighting the unmet need for safer and more effective treatments. Dotinurad offers a compelling alternative with its potential to minimize renal toxicity while providing potent and selective uric acid excretion, positioning it as a potential game-changer in the treatment of gout.

Expanding Pipeline and Reshaping the Global Landscape

Crystalys Therapeutics plans to use the new funding to advance not only the Phase 3 RUBY and TOPAZ trials but also a Phase 2 AMETHYST study in patients with gout and tophi, as well as an open-label extension study to gather long-term safety data. The company's ability to secure additional substantial funding within a year of emerging from stealth mode with a $205 million Series A round demonstrates the strength of its pipeline and execution capabilities. With the robust growth of the gout treatment market, the successful launch of dotinurad in the US and European markets could disrupt the market currently dominated by multinational pharmaceutical companies and establish a strong independent commercial presence.